Targeting Metabotropic Glutamate Receptors as a New Strategy Against Levodopa-Induced Dyskinesia in Parkinson's Disease?

被引：12
作者：
Picconi, Barbara [1 ]
Calabresi, Paolo [1 ,2 ]
机构：
[1] IRCCS, Fdn Santa Lucia, Rome, Italy
[2] Univ Perugia, Osped S Maria della Misericordia, Neurol Clin, I-06156 Perugia, Italy
来源：
MOVEMENT DISORDERS | 2014年 / 29卷 / 06期
关键词：
Parkinson's disease; mGluR5; dyskinesia; levodopa therapy; experimental animal models; DOPA-INDUCED DYSKINESIA; ALLOSTERIC MODULATORS; SYNAPTIC PLASTICITY; MGLUR5; ANTAGONIST; RAT MODEL; STRIATUM; TRANSMISSION; MECHANISMS; ANXIETY; AFQ056;
D O I：
10.1002/mds.25851
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results. (c) 2014 International Parkinson and Movement Disorder Society
引用
收藏
页码：715 / 719
页数：5
相关论文
共 38 条
[11]   Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson's Disease [J].
Duty, Susan .
CNS DRUGS, 2012, 26 (12) :1017-1032
[12]  
Fahn S, 2000, ANN NEUROL, V47, pS2
[13]  
Fox Chris, 2006, Neuropsychiatr Dis Treat, V2, P121, DOI 10.2147/nedt.2006.2.2.121
[14]   Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats [J].
Gravius, Andreas ;
Dekundy, Andrzej ;
Nagel, Jens ;
More, Lorenzo ;
Pietraszek, Malgorzata ;
Danysz, Wojciech .
JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (12) :1609-1619
[15]   Glutamatergic influences on the basal ganglia [J].
Greenamyre, JT .
CLINICAL NEUROPHARMACOLOGY, 2001, 24 (02) :65-70
[16]   The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys [J].
Gregoire, Laurent ;
Morin, Nicolas ;
Ouattara, Bazoumana ;
Gasparini, Fabrizio ;
Bilbe, Graeme ;
Johns, Donald ;
Vranesic, Ivo ;
Sahasranaman, Srikumar ;
Gomez-Mancilla, Baltazar ;
Di Paolo, Therese .
PARKINSONISM & RELATED DISORDERS, 2011, 17 (04) :270-276
[17]   Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases [J].
Gubellini, P ;
Pisani, A ;
Centonze, D ;
Bernardi, G ;
Calabresi, P .
PROGRESS IN NEUROBIOLOGY, 2004, 74 (05) :271-300
[18]   Corticostriatal LTP requires combined mGluR1 and mGluR5 activation [J].
Gubellini, P ;
Saulle, E ;
Centonze, D ;
Costa, C ;
Tropepi, D ;
Bernardi, G ;
Conquet, F ;
Calabresi, P .
NEUROPHARMACOLOGY, 2003, 44 (01) :8-16
[19]  
Gubellini P, 2002, J NEUROSCI, V22, P6900
[20]   Selective involvement of mGlu1 receptors in corticostriatal LTD [J].
Gubellini, P ;
Saulle, E ;
Centonze, D ;
Bonsi, P ;
Pisani, A ;
Bernardi, G ;
Conquet, F ;
Calabresi, P .
NEUROPHARMACOLOGY, 2001, 40 (07) :839-846
1234